Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - paracetamol, quantity: 500 mg; diphenhydramine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: stearic acid; croscarmellose sodium; purified talc; potassium sorbate; povidone; maize starch; titanium dioxide; hypromellose; macrogol 3350; indigo carmine aluminium lake - for the temporary relief of pain when associated with sleeping difficulty, for example: headache, migraine, backache, arthritis, rheumatic and muscle pain, neuralgia, toothache or period pain. relief of fever.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

advagen pharma ltd - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

Ingilterra - Ingliż - myHealthbox

wockhardt uk ltd - amitriptyline hydrochloride - oral solution - 10 mg/5ml - it is indicated for the treatment of: symptoms of depression (especially where sedation is required); nocturnal enuresis where organic pathology is excluded.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bio circuitry pty ltd - 60769 - pain-relief microcurrent skin patch - a non-sterile, self-adhesive patch intended for dermal application (to the skin) for the relief of localised pain, enhancement of local circulation and/or muscle relaxation. wearing the patch generates a microcurrent that can relieve acute pain such as strains, muscular pain and sporting injury and/or chronic pain including lumbago and rheumatic complaints. not intended for application to open wounds.

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - amitriptyline hydrochloride - oral tablet - 25mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - amitriptyline hydrochloride - oral tablet - 25mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - amitriptyline hydrochloride - oral tablet - 25mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - amitriptyline hydrochloride - oral tablet - 25mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - amitriptyline hydrochloride - oral tablet - 25mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - amitriptyline hydrochloride - oral tablet - 25mg